

Scientific Program STATE OF THE ART AND NEXT QUESTIONS

Thursday, May 15th 2025

ANU - Museum of the Jewish People, Tel Aviv

08:00-09:00 **Registration, Gathering, & Exhibition**

09:00-09:30 **Opening Remarks**

Hagop Kantarjian, MD, Chair of the Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, USA

Eytan Wirthem, MD, MHA, CEO - Beilinson & Hasharon Hospitals - Rabin Medical Center, Clalit Health Services, Israel

Karen Avraham, PhD, Dean of the Faculty of Medical & Health Sciences, Tel-Aviv University, Israel

Galia Stemer, MD, in the name of the Israel Society of Hematology and Blood Transfusions

Gal Markel, MD, Head, Davidoff Cancer Center, Rabin Medical Center, Israel

Mr. Paul Davidoff, on behalf of the Davidoff Family

Pia Raanani, MD, Head, Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Israel

09:30-10:50 **Session 1 - Chronic Lymphocytic Leukemia**

Chairpersons - Liron Hofstetter, MD | Yair Herishanu, MD

09:30-09:50 Prognostication and Management of Early Stage CLL

Barbara Eichhorst, MD, University Hospital of Cologne, Germany

09:50-10:10 BTK Inhibitors: Long-Term Responses and Differential Responses in IGHV Subsets

Jan Burger, MD, University of Texas MD Anderson Cancer Center, Houston, USA

09:10-10:30 Chronic Lymphocytic Leukemia: Evolution of Frontline Treatment

Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, USA

10:30-10:50 Management of Relapsed/Refractory CLL and New Treatments on the Horizon

William (Bill) Wierda, MD, University of Texas MD Anderson Cancer Center, Houston, USA

10:50-11:10 **Coffee Break & Exhibition**

11:10-12:20 **Session 2 - Plasma Cell Dyscrasias**

Chairpersons - Iuliana Vaxman, MD | Moshe Gatt, MD

11:10-11:30 High-Risk Smoldering Multiple Myeloma: Is There a Simple Solution?

Angela Dispenzieri, MD, Mayo Clinic Rochester Minnesota, USA

11:30-11:50 Should Patients Still Undergo BMT for Myeloma?

Morie Gertz, MD, Mayo Clinic Rochester Minnesota, USA

11:50-12:10 Real World Updates for RRMM T Cell-Redirecting Therapies

Krina Patel, MD, University of Texas MD Anderson Cancer Center, Houston, USA

12:10-12:20 **Panel Discussion**

12:20–13:05 **Lunch & Exhibition**

13:05–14:15 **Session 3 – Acute Myeloid Leukemia**

Chairpersons: Ofir Wolach, MD | Irina Amitai, MD

- 13:05–13:25 Mutant NPM1 AML: The Poster Child for MRD Use
Richard Stone, MD, Dana Farber Cancer Institute, Boston, USA
- 13:25–13:45 Emerging Novel Therapeutics in AML
Gail Roboz, MD, Weill Cornell Medicine, The New York Presbyterian Hospital, New York, USA
- 13:45–14:05 Treating Acute Myeloid Leukemia in 2025
Courtney DiNardo, MD, University of Texas MD Anderson Cancer Center, Houston, USA
- 14:05–14:15 **Panel Discussion**

14:15–14:30 **Coffee Break & Exhibition**

14:30–16:30 **Session 4 – Lymphoma**

Chairpersons: Nadav Sarid, MD | Uri Abadi, MD

- 14:30–14:50 Next Steps in Hodgkin Lymphoma
Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, NY, USA
- 14:50–15:10 Incorporating Biology into Upfront Therapy for Systemic T-Cell Lymphomas
Steve Horwitz, MD, Memorial Sloan Kettering Cancer Center, NY, USA
- 15:10–15:30 Updates in PTCL Treatment
Swaminathan Padmanabhan Iyer, MD, University of Texas MD Anderson Cancer Center, Houston, USA
- 15:30–15:50 Navigating the Diffuse Large B-cell Lymphoma Landscape in 2025
Gilles Salles, MD, Memorial Sloan Kettering Cancer Center NY, USA
- 15:50–16:10 Updates in Marginal Zone Lymphoma
Izidore Lossos, MD, Division of Hematology, Department of Medicine, University of Miami and Sylvester Comprehensive Cancer Center
- 16:10–16:30 Mantle Cell Lymphoma: Current Standards and Future Studies
Martin Dreyling, MD, PhD, Ludwig Maximilian, University of Munich, Germany

16:30–17:20 **Session 5 – Quality of Life in Hematological Disorders**

Chairpersons: Alon Rozental, MD | Ariel Aviv, MD

- 16:30–16:50 Quality of Life in AML and MDS
Fabio Efficace, MD, Fondazione GIMEMA – Franco Mandelli Onlus, Roma, Italy
- 16:50–17:10 Quality of Life in CML
Philipp Le Coutre, MD, Charité – Universitätsmedizin Berlin, Germany
- 17:10–17:20 **Panel Discussion**
- 17:20–17:30 **Closing Remarks**

Friday, May 16th 2025

Port Tower Hotel, Tel Aviv

08:00–08:30 **Gathering**

08:30–10:30 **Session 6 – Myeloproliferative & Myelodysplastic Disorders**

Chairpersons: Adi Shacham – Abulafia, MD | Galia Stemer, MD

- 08:30–08:50 Myeloproliferative Neoplasms
Lucia Masarova, MD, University of Texas MD Anderson Cancer Center, Houston, USA
- 08:50–09:10 Management of Systemic Mastocytosis in 2025
Jason Gotlib, MD, Hematology, Stanford Cancer Center Palo Alto, Palo Alto California
- 09:10–09:30 New Paradigms in MDS
Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, USA
- 09:30–09:50 How Can We Improve Outcomes in Patients with Higher Risk MDS
David A Sallman, MD, Moffitt Cancer Center Tampa, Florida, USA
- 09:50–10:10 How I Treat CMML
Eric Padron, MD, Moffitt Cancer Center, Tampa, Florida, USA
- 10:10–10:30 How to Choose the Best Therapeutic Approach in LR MDS
Valeria Santini, MD, University of Florence, Florence, Italy

10:30–12:10 **Session 7 – Chronic Myeloid Leukemia**

Chairpersons: Pia Raanani, MD | Noam Benyamini, MD

- 10:30–10:50 Challenges in the Upfront Treatment of CML
Delphine Rea, MD, Hopital Saint-Louis, Paris, France
- 10:50–11:10 Mechanisms of Resistance to Asciminib
Simona Soverini, PhD, Alma Mater Studiorum Universita di Bologna, Italy
- 11:10–11:30 Questions and Answers on CML Treatment that Can Derive from the Analysis of Real-Life Data
Giuseppe Saglio, MD, University of Turin, Italy
- 11:30–11:50 How I Manage CML at MD Anderson in 2025
Hagop Kantarjian, MD, University of Texas MD Anderson Cancer Center, Houston, USA
- 11:50–12:10 **Panel Discussion**

12:10–12:30 **Coffee Break**

12:30–13:30 **Session 8 – Cellular Therapy**

Chairpersons: Batia Avni, MD | Avichai Shimoni, MD

- 12:30–12:50 Current State and Future Directions of Cell Therapy for B-cell Lymphomas
Nirav N Shah, MD, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
- 12:50–13:10 Role of Allogeneic Transplantation in Adult ALL in 2025
Issa F Khouri, MD, University of Texas MD Anderson Cancer Center, Houston, USA
- 13:10–13:30 Cellular Therapy for AML – The Next Questions
Koen van Besien, MD, PhD, UH Seidman Cancer Center, Cleveland, Ohio, USA

13:30-14:55

Session 9 - Acute Lymphoblastic Leukemia

Chairpersons: Anat Gafter-Gvili, MD | Yakir Moshe, MD

13:30-13:50 ALL Research and Therapy at MD Anderson in 2025

Hagop Kantarjian, MD, *University of Texas MD Anderson Cancer Center, Houston, USA*

13:50-14:10 How Blinatumomab-Based Treatment is Changing the Management and Outcome of B-ALL

Robin Foà, MD, *Department of Translational and Precision Medicine, Sapienza, University of Rome, Rome, Italy*

14:10-14:30 Frontline Treatment of Ph+ ALL and the Emerging Role of Chemotherapy-Free Regimens

Nicholas J Short, MD, *University of Texas MD Anderson Cancer Center, Houston, USA*

14:30-14:55 **Panel Discussion**

14:55-15:00 **Closing Remarks**

DIAMOND



PLATINUM

Johnson & Johnson

abbvie

AstraZeneca 

GOLD

 Bristol Myers Squibb®



 GILEAD

sanofi

MEDISON 

Lilly

 NEOPHARM ISRAEL
NEOPHARM GROUP

 astellas